Ameriprise Financial Inc. Has $20.08 Million Stake in Charles River Laboratories International, Inc. (CRL)

Ameriprise Financial Inc. raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 185,847 shares of the medical research company’s stock after purchasing an additional 12,903 shares during the quarter. Ameriprise Financial Inc. owned 0.39% of Charles River Laboratories International worth $20,076,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Alps Advisors Inc. grew its holdings in shares of Charles River Laboratories International by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock valued at $541,000 after acquiring an additional 14 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of Charles River Laboratories International by 0.5% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,953 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 33 shares in the last quarter. World Asset Management Inc grew its holdings in shares of Charles River Laboratories International by 2.2% in the second quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 59 shares in the last quarter. M&T Bank Corp grew its holdings in shares of Charles River Laboratories International by 1.8% in the second quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 76 shares in the last quarter. Finally, Chartwell Investment Partners LLC grew its holdings in shares of Charles River Laboratories International by 0.4% in the second quarter. Chartwell Investment Partners LLC now owns 50,028 shares of the medical research company’s stock valued at $5,060,000 after acquiring an additional 186 shares in the last quarter. 96.27% of the stock is owned by institutional investors.

In other news, Director C Richard Reese sold 10,227 shares of the firm’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total value of $1,047,244.80. Following the completion of the transaction, the director now directly owns 51,444 shares of the company’s stock, valued at $5,267,865.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. Over the last three months, insiders have acquired 10,500 shares of company stock valued at $2,885 and have sold 1,016,392 shares valued at $1,995,395. 2.20% of the stock is currently owned by corporate insiders.

Charles River Laboratories International, Inc. (CRL) opened at $103.84 on Monday. Charles River Laboratories International, Inc. has a twelve month low of $73.13 and a twelve month high of $119.05. The firm has a market capitalization of $4,918.02, a price-to-earnings ratio of 20.40, a price-to-earnings-growth ratio of 1.66 and a beta of 0.89. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The business had revenue of $464.23 million during the quarter, compared to analyst estimates of $458.93 million. During the same period in the prior year, the company earned $1.18 earnings per share. Charles River Laboratories International’s revenue was up 9.0% compared to the same quarter last year. equities research analysts predict that Charles River Laboratories International, Inc. will post 5.13 EPS for the current year.

CRL has been the subject of several recent analyst reports. ValuEngine lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Robert W. Baird reaffirmed a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a report on Friday, September 1st. Credit Suisse Group reissued a “neutral” rating and set a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories International in a report on Monday, October 16th. Zacks Investment Research lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Finally, SunTrust Banks reissued a “buy” rating and set a $113.00 price objective on shares of Charles River Laboratories International in a report on Friday, November 17th. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $106.63.

ILLEGAL ACTIVITY WARNING: “Ameriprise Financial Inc. Has $20.08 Million Stake in Charles River Laboratories International, Inc. (CRL)” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://ledgergazette.com/2017/12/11/ameriprise-financial-inc-has-20-08-million-stake-in-charles-river-laboratories-international-inc-crl.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply